Literature DB >> 30917908

Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism.

Zhimin Fan1, Guihai Wu1, Minghui Yue1, Jianfeng Ye1, Yequn Chen1, Bayi Xu1, Zhouwu Shu1, Jinxiu Zhu1, Nan Lu1, Xuerui Tan2.   

Abstract

AIMS: Renin-angiotensin system modulates cardiac structure independent of blood pressure. The present study aimed at investigating whether single nucleotide polymorphism (SNP) and haplotype of angiotensin converting enzyme 2 (ACE2) could influence blood pressure and the susceptibility to hypertensive left ventricular hypertrophy (LVH). SUBJECTS AND METHODS: A total of 647 patients (347 females and 300 males) with newly diagnosed mild to moderate essential hypertension were enrolled in a blood pressure matched, case-control study. Four ACE2 tagSNPs (rs2074192, rs4646176, rs4646155 and rs2106809) were genotyped and major haplotypes consisting of these four SNPs were reconstructed for all subjects. KEY
FINDINGS: In females, minor alleles of ACE2 rs2074192 and rs2106809 respectively conferred a 2.1 and 2.0 fold risk for LVH. ACE2 haplotype TCGT increased the risk for LVH while another haplotype CCGC decreased the risk in females. The covariates-adjusted mean left ventricular mass index was 11% greater in TCGT haplotype carriers than in noncarriers in women. In females, the covariates-adjusted mean systolic blood pressure was 3.4 mm Hg lower in CCGC haplotype carriers than in noncarriers. In males, the covariates-adjusted mean systolic blood pressure was 2.4 mm Hg lower in CCGC haplotype carriers than in noncarriers. SIGNIFICANCE: ACE2 tagSNPs rs2074192 and rs2106809 as well as major haplotypes CCGC and TCGT may serve as novel risk markers for LVH in hypertensive patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin converting enzyme 2; Haplotype; Left ventricular hypertrophy; Renin-angiotensin system; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2019        PMID: 30917908     DOI: 10.1016/j.lfs.2019.03.059

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  27 in total

1.  ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review.

Authors:  Gomaa Mostafa-Hedeab
Journal:  Rep Biochem Mol Biol       Date:  2020-04

Review 2.  Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Authors:  Daniel Lenihan; Joseph Carver; Charles Porter; Jennifer E Liu; Susan Dent; Paaladinesh Thavendiranathan; Joshua D Mitchell; Anju Nohria; Michael G Fradley; Iskra Pusic; Keith Stockerl-Goldstein; Anne Blaes; Alexander R Lyon; Sarju Ganatra; Teresa López-Fernández; Rupal O'Quinn; Giorgio Minotti; Sebastian Szmit; Daniela Cardinale; Jose Alvarez-Cardona; Giuseppe Curigliano; Tomas G Neilan; Joerg Herrmann
Journal:  CA Cancer J Clin       Date:  2020-09-10       Impact factor: 508.702

3.  Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis.

Authors:  Nasser Pouladi; Sepehr Abdolahi
Journal:  Mol Genet Genomic Med       Date:  2021-04-05       Impact factor: 2.183

4.  Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.

Authors:  Jiawei Chen; Quanlong Jiang; Xian Xia; Kangping Liu; Zhengqing Yu; Wanyu Tao; Wenxuan Gong; Jing-Dong J Han
Journal:  Aging Cell       Date:  2020-06-19       Impact factor: 9.304

Review 5.  COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches.

Authors:  F Moccia; A Gerbino; V Lionetti; M Miragoli; L M Munaron; P Pagliaro; T Pasqua; C Penna; C Rocca; M Samaja; T Angelone
Journal:  Geroscience       Date:  2020-05-20       Impact factor: 7.713

Review 6.  Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.

Authors:  Celestino Sardu; Jessica Gambardella; Marco Bruno Morelli; Xujun Wang; Raffaele Marfella; Gaetano Santulli
Journal:  J Clin Med       Date:  2020-05-11       Impact factor: 4.241

Review 7.  Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.

Authors:  Soudeh Ghafouri-Fard; Rezvan Noroozi; Mir Davood Omrani; Wojciech Branicki; Ewelina Pośpiech; Arezou Sayad; Krzysztof Pyrc; Paweł P Łabaj; Reza Vafaee; Mohammad Taheri; Marek Sanak
Journal:  Vascul Pharmacol       Date:  2020-05-11       Impact factor: 5.773

8.  Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors.

Authors:  Xian Zhou; Jingkang Zhu; Tao Xu
Journal:  Clin Exp Hypertens       Date:  2020-05-13       Impact factor: 1.749

Review 9.  Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19.

Authors:  Rafael Silva Lima; Luiz Paulo Carvalho Rocha; Paula Rocha Moreira
Journal:  Cell Biochem Funct       Date:  2021-06-01       Impact factor: 3.963

Review 10.  COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?

Authors:  A Aleksova; F Ferro; G Gagno; C Cappelletto; D Santon; M Rossi; G Ippolito; A Zumla; A P Beltrami; G Sinagra
Journal:  J Intern Med       Date:  2020-06-08       Impact factor: 13.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.